Company Research Report: Sumitomo Pharma Co., Ltd.

Company Overview

Name: Sumitomo Pharma Co., Ltd.
Mission: To broadly contribute to society by creating value through innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide.

Founded: April 1, 2022, as Sumitomo Pharma (name changed from Sumitomo Dainippon Pharma)

Key People:

• Toru Kimura: Representative Director, President, and CEO

Headquarters: Osaka, Japan

Number of Employees: 4,980 (as of FY2023)

Revenue: No information is available

Known For: A leader in pharmaceuticals with a focus on the Psychiatry & Neurology and Oncology disease areas. The company also focuses on regenerative medicine/cell therapy and non-pharmaceutical solutions.

Products

Product Offerings:

• ORGOVYX®: Therapeutic for advanced prostate cancer

• MYFEMBREE®: Therapeutic for uterine fibroids

• GEMTESA®: Therapeutic agent for overactive bladder (OAB)

• RETHYMIC®: Cultured thymus tissue for pediatric congenital athymia

• LATUDA®: An atypical antipsychotic (launched in the U.S. and other regions)

• DSP-5336 and TP-3654: Oncology products under development

High-Level Description & Key Features:

• Sumitomo Pharma provides innovative pharmaceuticals primarily in Psychiatry & Neurology and Oncology. Products focus on critical therapeutic areas with high unmet medical needs, aiming to improve patient quality of life.

Recent Developments

Recent Developments:

• Sumitomo Pharma America to present new investigational data at the 2024 American Society of Hematology Annual Meeting, focusing on cutting-edge research and development.

• Entered into an agreement with the Tokyo Metropolitan Government for a health promotion project for the elderly, underlining the company's commitment to community health initiatives.

New Products Launched:

• RETHYMIC®: Launched in the U.S.

New Features Added to Existing Products: No information is available

Partnerships:

• Amended agreement for joint development and commercialization in the Psychiatry & Neurology area with Otsuka Pharmaceutical Co., Ltd.

Sumitomo Pharma focuses on its strategic vision of becoming a “Global Specialized Player” by 2033 with initiatives in key disease areas incorporating advanced science to create leading pharmaceuticals and therapeutic solutions.